Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Enovix Corporation (ENVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Enovix Corporation — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Enovix Corporation trades at $2.38 (market cap $550.82M). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 5.2× Enovix Corporation's market cap, and Enovix Corporation is more actively traded (5,977,872 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Enovix Corporation for 11 Days on average.
| DYN | ENVX | |
|---|---|---|
Market Cap | $2.86B | $550.82M |
Volume | 3,341,579 | 5,977,872 |
Sector | Health | Industrials |
52-Week High | $26.78 | $13.19 |
52-Week Low | $14.60 | $2.44 |
Typical Hold Time | 0 Days | 11 Days |
Enterprise Value | $2.18B | $612.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
ENVX trades at $2.51, down 3.09% on the day, reflecting bearish technical signals and negative profitability. The company reported a net loss of -$156.74M in 2025, with revenue of $31.82M, while recent quarterly EPS has consistently beaten expectations. Key developments include a CEO transition in August 2026 and expansion of drone battery capacity in South Korea.
Despite deep losses and cash burn, analyst consensus remains bullish with a $9.60 price target, citing potential in defense and smartphone battery markets. Risks include high cash burn, leadership changes, and competitive pressures. The stock's outlook hinges on successful commercialization and margin improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →
